A Phase 1 interventional study of lozenges containing propolis in Plaque Induced Gingivitis, Mouth Diseases and Periodontal Diseases, sponsored by Al-Mustansiriyah University. Completed at 1 site in Iraq. Open to male participants aged 19 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Al-Mustansiriyah University · Phase 1, Interventional, and Treatment
The goal of this clinical trial is to test the efficiency of using lozenges containing propolis extract over one week to control gingival inflammation and plaque accumulation by measuring the clinical periodontal parameters (Gingival index, plaque index) in comparison with a control group given oral hygiene instruction only in patients with biofilm induced gingivitis (moderate gingivitis)
Objectives:
100 subjects will be enrolled, who show generalized gingivitis (moderate gingivitis) with no Periodontal pocket depth>3 mm, intact periodontium, and no loss of periodontal attachment), caused by the accumulation of plaque. 50 subjects are case that given a lozenge containing propolis and oral hygiene instructions, and 50 subjects were control that were given oral hygiene instructions only. The participants will be asked to chew a lozenge twice per day and Discontinuation of the lozenges will be advised in cases of any allergic reaction. in baseline visit at the beginning, Saliva collection for IL-1β and IL-10 measurement, then clinical periodontal parameters examination starting with gingival index (Loe and Silness in 1963) designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency, and bleeding on probing. A periodontal probe will be run along the gingival margin. The gingiva surrounding the tooth is assessed at four sites: mesio-facial papilla, facial marginal gingiva, disto-facial papilla and lingual marginal gingiva. Then finally followed by the Plaque Index (Loe and Silness in 1963). the data had been recorded from labial/buccal and lingual/palatal surfaces.
First visit after 7 days, from the baseline visit. Saliva collection and clinical periodontal parameters scoring (GI, PI) will be performed again as described at the baseline visit.
109 studies on the registry are indexed under Mouth Diseases; 18 are open to participants now.
This study's enrollment of 100 is below the median of 120 across 81 interventional studies indexed under Mouth Diseases.
Browse Mouth Diseases studies →Al-Mustansiriyah University is the lead sponsor of 31 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1. Individuals with chronic illnesses, immunocompromised individuals, pregnant women, those on contraceptive medications, and breastfeeding mothers.
2. People who use mouthwash at the moment or any preventive modalities. 3. Those taking anti-inflammatory drugs and antibiotics both during the study and in the final four weeks prior.
4. Individuals have a history of hypersensitivity to any substance utilized in the current investigation.
5. Individuals who have undergone a recent tooth extraction. 6. Individuals with Periodontal pocket depth Equal or less than 4 or attachment loss.
7. Individuals who smoke. 8. Individuals with orthodontic equipment, removable dentures, implants.
lozenges containing propolis Participants will be given the test interventions, lozenges containing propolis, and will be asked to chew twice per day and will be instructed to ordinary oral hygiene instruction, No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
Drug: lozenges containing propolis
Participants will be instructed to ordinary oral hygiene instruction only, No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
lozenges containing propolis Participants will be given the test interventions, lozenges containing propolis, and will be asked to chew twice per day and will be instructed to ordinary oral hygiene instruction, No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days
Also known as: bee glue
Changes in the clinical periodontal parameter (Gingival index)
Subjects will undergo the measurement of the gingival index according to (Loe \& Silness in 1963), designed to assess the severity and quality of gingival inflammation in an individual or population. The gingival inflammation is assessed on the basis of color, consistency, and bleeding on probing. The Gingival Index (GI) scores each site on a 0 to 3 scale Score 0 : Normal gingiva score 1: Mild Inflammation- slight change in color, Slight oedema. No bleeding on probing. score 2: Moderate inflammation-redness, oedema and glazing. Bleeding on probing. score 3: Sever inflammation-marked redness and edema. Ulceration. Tendency to spontaneous bleeding.
Time frame: (0, 7days)
Changes in the clinical periodontal parameter (Plaque index )
To determine the patients' plaque index, their dental plaque thickness was evaluated by probing the mesial, distal, buccal, and palatal surfaces of all teeth using a Williams periodontal probe. The individual's plaque index was determined by summing the values obtained for each tooth and calculating the averages.Silness \& Löe (Silness \& Löe,1964) reference values were taken as a basis The Plaque Index (PI) scores each site on a 0 to 3 scale Score 0 : No plaque is in the area adjacent to the gingiva. Score 1: There is a plaque in the form of a thin film on the gingival margin. Score 2: There is a visible plaque in the gingival pocket and gingival margin. Score 3: There is a dense plaque in the gingival pocket and on the gingival margin.
Time frame: (0, 7days)
Changes in salivary cytokines (IL- 1β , IL-10)
ELISA kit will analyze salivary interleukins, and concentrations are measured according to manufacturing instructions, were picogram per liter for interleukin 1 beta levels and nanogram per milliliter for interleukin 10 levels 0 day: Saliva collection for IL-1β and IL-10 measurement, then clinical periodontal parameters examination starting with the gingival index finally followed by the Plaque index 7 days: Saliva collection and clinical periodontal parameters scoring (GI, PI) will be performed again as described at the baseline visit,
Time frame: (0, 7days)
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al-Mustansiriyah University